WHO ICTRP trial
CA209-7G8/ONO-4538-110:Phase 3
JPRN-jRCT2031210118 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031210118 |
|---|---|
| Public title | CA209-7G8/ONO-4538-110:Phase 3 |
| Scientific title | CA209-7G8/ONO-4538-110:A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants With High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment With BCG |
| Primary sponsor | Hirashima Yoshinori |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | USA;Japan;Spain;Japan;UK;Japan;France;Japan;Canada;Japan;Argentina;Japan;Romania;Japan;Netherlands;Japan;Italy;Japan;Australia;Japan;Germany;Japan;Brazil;Japan;Chile;Japan;Greece;Japan;Sweden;Japan;Au… |
| Conditions | High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment With BC |
| Interventions | Drug: nivolumab or placebo Biological: Bacillus Calmette-Guerin (BCG) |
| Registration date | May 28, 2021 |
| Target size | 46 |
| Secondary IDs | NCT04149574 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: